Biotechnology - aldoxorubicin

Filter

Current filters:

aldoxorubicin

Popular Filters

CytRx: all eyes on aldoxorubicin, say analysts

03-09-2013

US biotech firm CytRx Corp (Nasdaq: CYTR) is entering a critical six-month period as aldoxorubicin delivers…

aldoxorubicinBiotechnologyCytRxFinancialOncologyResearch

CytRx to focus on aldoxorubicin after tamibarotene demise; Loss narrows

10-05-2013

US biotech firm CytRx Corp (Nasdaq: CYTR) says that it will now focus on the clinical development of…

aldoxorubicinBiotechnologyCytRxFinancialOncologyResearchtamibarotene

Problems for competitor likely to benefit CytRx' aldoxorubicin

28-03-2013

The failure of Ziopharm's palifosfamide in metastatic soft tissue sarcoma (STS; The Pharma Letter March…

aldoxorubicinBiotechnologyCytRxFinancialOncologypalifosfamidePharmaceuticalResearch

Parexel

Parexel

Back to top